Rubicon Research

Rubicon Research's promoter, General Atlantic Singapore RR Pte. Ltd., sold 1.40 crore equity shares in on-market transactions on 25 and 26 August 2026. The sale represented 8.45% of the company's equity share capital and 8.37% of its fully diluted share capital. General Atlantic's holding fell from 5.93 crore shares, or 35.79%, to 4.53 crore shares, or 27.34%; its fully diluted holding fell from 35.45% to 27.07%. The company's total equity share capital remained ₹16.55 crore after the transaction. Rubicon Research generated about ₹1,754 crore of revenue in FY26, with roughly 99% tied to the US market.

Powered by Tijori

Aug 26 (Reuters) - BSE:

• GENERAL ATLANTIC SELLS 13 MILLION SHARES OF RUBICON RESEARCH VIA BULK DEAL

Source text: [ID:]

Further company coverage: RUBI.NS

(([email protected];))

** Shares of India's Rubicon Research RUBI.NS jump 6.38% to 1,733.6 rupees

** Stock on track to snap three session of losses, if gains hold

** Co's first quarter profit rose about two-fold year-on-year to 847.8 million rupees ($8.87 million)

** Co also posted 51.6% year-on-year rise in June quarter revenue to 5.34 billion rupees

** Trading vols at 1.37 million shares vs 30-day volumes of 247,851 shares

** YTD stock up 152.77%

($1 = 95.6100 Indian rupees)

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

By Bharath Rajeswaran

Aug 13 (Reuters) - Global index provider MSCI said on Thursday it will add four Indian companies to its widely tracked Global Standard index and remove three as part of its August review, underscoring the continuing churn in India's representation within global passive portfolios.

The changes will be implemented after the close of trading on August 31, 2026, and take effect on September 1, MSCI said.

Laurus Labs LAUL.NS, an active pharmaceutical ingredients manufacturer; Lenskart LENS.NS, an omnichannel eyewear retailer; Adani Energy Solutions ADAI.NS, the Adani Group's power transmission and distribution arm, and Groww BILO.NS, a digital investment and broking platform, will enter the index.

They will replace tyre maker Balkrishna Industries BLKI.NS, credit-card issuer SBI Cards SBIC.NS, and building-materials company Astral ASTL.NS. Following the reshuffle, the number of Indian constituents in the key MSCI index will rise to 166 from 165.

India's weightage in the global standard index will also rise to 11.9% from 11.8%, according to Nuvama Alternative and Quantitative Research.

The inclusion is expected to trigger significant buying by exchange-traded funds and other passive investors that replicate MSCI benchmarks.

Nuvama Alternative and Quantitative Research estimates potential inflows of about $598 million for Laurus Labs, $352 million for Lenskart, $310 million for Adani Energy Solutions and $256 million for Groww.

Conversely, Balkrishna Industries, SBI Cards and Astral could see estimated passive outflows of $169 million, $143 million and $138 million, respectively.

The review also recalibrated weights among existing index members. Eternal ETEA.NS is projected to attract the largest incremental passive inflow, at around $674 million, following an increase in its weight. Adani Enterprises ADEL.NS and Adani Ports APSE.NS could receive about $202 million and $77 million, respectively.

Reliance Industries RELI.NS is estimated to face outflows of roughly $523 million, while Jio Financial Services JIOF.NS may see $61 million in outflows.

Separately, MSCI's Small Cap index review added companies including Amagi Media Labs AMAI.NS, Ather Energy ATHR.NS, Clean Max CLEM.NS, E2E Networks EENE.NS, Embassy Developments EMBS.NS, Patanjali Foods PAFO.NS, Rubicon Research RUBI.NS, Sedemac Mechatronics SEDE.NS, Sky Gold and Diamonds SKYG.NS, United Breweries UBBW.NS, Urban Company URBN.NS and WeWork India WEWO.NS, while removing 19 stocks.

(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Rashmi Aich)

(([email protected]; +91 9769003463;))

July 3 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH - US FDA CONDUCTS UNANNOUNCED INSPECTION OF PITHAMPUR FACILITY FROM JUNE 29 TO JULY 3, 2026

• RUBICON RESEARCH - FORM 483 WITH 2 PROCEDURAL OBSERVATIONS ISSUED; NO DATA INTEGRITY ISSUES

Source text: ID:nBSE9SLh7G

Further company coverage: RUBI.NS

(([email protected];))

** Drug formulations firm Rubicon Research's RUBI.NS shares rise 12.2% to 1,128 rupees, touching an all-time high

** Q4 profit jumps 111.8%; revenue from operations up 43.5%

** Recommends dividend of 1.5 rupees/shr

** Says revenue traction is likely to continue to be stronger than anticipated

** Adds, strong revenue traction coupled with own manufacturing capacity constraint had led to a larger reliance on outsourced manufacturing since the last quarter

** Says larger than anticipated reliance on outsourced manufacturing could further contract gross margin % in the near term

** 24 products were under review by U.S. FDA as of 31 March, RUBI.NS says

** YTD, stock up 66% vs 1% decline in Nifty Smallcap 500 Index .NIFTYSMALLCAP500

(Reporting by Abhinav Parmar in Bengaluru)

(([email protected];))

April 22 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH LTD - TOTAL DEMAND RAISED AMOUNTS TO 172.5 MILLION RUPEES

• RUBICON RESEARCH LTD - RECEIVES ORDER FROM INCOME TAX AUTHORITY

Source text: ID:nBSE5MWsZ

Further company coverage: RUBI.NS

(([email protected];))

April 15 (Reuters) - Rubicon Research Ltd RUBI.NS:

• TO BUY 85% STAKE IN ARINNA LIFESCIENCES

• DEAL VALUED AT 1.76 BILLION RUPEES

• DEAL FOR PRICE OF ABOUT 158.53 RUPEES PER SHARE

Source text: ID:nBSE387jMF

Further company coverage: RUBI.NS

(([email protected];;))

** Shares of Rubicon Research RUBI.NS jump as much as 13% to a record high of 789 rupees, last up 4%

** Stock up for a third straight session

** Pharmaceutical formulations co's Q3 consol net profit nearly doubles to 728 mln rupees ($8.04 mln); rev from ops rises 51.7% y/y

** Stock up about ~21 from market debut in October 16, 2025

($1 = 90.5200 Indian rupees)

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Feb 3 (Reuters) - Rubicon Research Ltd RUBI.NS:

• DEC-QUARTER CONSOL NET PROFIT 728 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.76 BILLION RUPEES

Source text: ID:nBSE4GS3ZJ

Further company coverage: RUBI.NS

(([email protected];))

Jan 30 (Reuters) - Rubicon Research Ltd RUBI.NS:

• TAX AUTHORITIES COMMENCE INSPECTION AT COMPANY OFFICES

• COMPANY FULLY COOPERATING WITH OFFICIALS

• BUSINESS OPERATIONS CONTINUE UNIMPACTED BY INSPECTION

Source text: ID:nNSE3Fv1J4

Further company coverage: RUBI.NS

(([email protected];))

Jan 6 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH LTD - UNIT GETS TAX DEMAND OF 41.9 MILLION RUPEES

Source text: ID:nNSE2lyKrH

Further company coverage: RUBI.NS

(([email protected];))

Nov 13 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH SEPT-QUARTER CONSOL NET PROFIT 538.5 MILLION RUPEES

• RUBICON RESEARCH SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.12 BILLION RUPEES

Source text: [ID:]

Further company coverage: RUBI.NS

(([email protected];))

** Shares of pharmaceutical formulations co Rubicon Research RUBI.NS rise 2.3% to 623 rupees

** Motilal Oswal initiates coverage with "buy" rating, PT of 740 rupees; first brokerage to cover stock - per data compiled by LSEG

** Brokerage estimates annualised growth of 29%, 32%, and 43% in rev, EBITDA, and PAT, respectively
** Says growth driven by new generic launches, stronger focus on prescription-led business in CNS therapy, stable

R&D productivity, tighter supply chain management

** Adds, Rubicon's consistent compliance track record provides a strong backbone for growth in earnings and

return ratios

** Since its listing earlier this month, RUBI down nearly 3%

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))